Search

Displaying results 1941 - 1950 of 9132 in total
  1. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction. … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization

  2. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    a potential therapeutic target. … [A216183] Topical pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following

  3. Drug

    Manidipine

    go.drugbank.com/drugs/DB09238
    ApprovedInvestigationalWithdrawn

    Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. … It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

    Products: MANIDIPINA DOC GENERICI, MANIDIPINA MYLAN GENERICS
  4. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for … Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza.

  5. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index
  6. Drug

    Etodolac

    go.drugbank.com/drugs/DB00749
    ApprovedInvestigationalVet approved

    Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties.

  7. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID). … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].

  8. Drug

    Melatonin

    go.drugbank.com/drugs/DB01065
    ApprovedInvestigationalNutraceuticalVet approved

    Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. … The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous … humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral

  10. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. … It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.